Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Completed · Phase 1/Phase 2

Conditions studied: Malignant Melanoma

In brief

AMP-005 is a Phase 1b/2 clinical trial designed to evaluate whether the new drug, imexon, can be administered in combination with the approved drug, dacarbazine (DTIC), for the treatment of patients with stage III or IV inoperable melanoma. The Phase 1b part of the study is designed to determine whether the two drugs can be safely combined together, and the Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether adding imexon to DTIC can improve the outcome for melanoma patients versus the findings from prior clinical studies of DTIC alone.

Key facts

Study ID
NCT00327600
Run by
AmpliMed Corporation
People needed
68
Starts
2005-07-01
Expected to finish
2007-12-01
Last updated by the study team
2010-09-15

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.